Takeda Pharmaceutical Company Limited – NYSE:TAK
Takeda Pharmaceutical Company Limited stock price today
$15.2
+1.92
+14.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Takeda Pharmaceutical Company Limited stock price monthly change
-1.26%
month
Takeda Pharmaceutical Company Limited stock price quarterly change
-1.26%
quarter
Takeda Pharmaceutical Company Limited stock price yearly change
-5.69%
year
Takeda Pharmaceutical Company Limited key metrics
Market Cap | 41.45B |
Enterprise value | 10.82T |
P/E | 11.42 |
EV/Sales | 2.38 |
EV/EBITDA | 8.70 |
Price/Sales | 1.46 |
Price/Book | 0.47 |
PEG ratio | N/A |
EPS | 47.69 |
Revenue | 3.78T |
EBITDA | 984.56B |
Income | 74.51B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 6.38% |
Oper. margin | 11.21% |
Gross margin | 55.23% |
EBIT margin | 11.21% |
EBITDA margin | 26.04% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTakeda Pharmaceutical Company Limited stock price history
Takeda Pharmaceutical Company Limited stock forecast
Takeda Pharmaceutical Company Limited financial statements
| Dec 2021 | 901.29B | 57.77B | 6.41% |
|---|---|---|---|
| Mar 2022 | 873.28B | -11.37B | -1.3% |
| Mar 2023 | 956.15B | 31.13B | 3.26% |
| Mar 2024 | 1.05T | -3.01B | -0.29% |
| Sep 2025 | 1.00T | 0 | |
|---|---|---|---|
| Oct 2025 | 1.00T | 0 | |
| Dec 2025 | 1.05T | 0 | |
| Mar 2026 | 1.03T | 0 |
Analysts Price target
Financials & Ratios estimates
| 2022-10-27 | 0.52 | 0.52 |
|---|
Paying a dividend greater than earnings.
3.84%
Yield TTM
| Payout ratio | 101.62% |
|---|
| 2020 | 11.12% |
|---|---|
| 2021 | 8.98% |
| 2022 | 10.41% |
| 2023 | 8.23% |
| 2024 | 8.77% |
| Sep 2022 | 14588847000000 | 7.87T | 53.98% |
|---|---|---|---|
| Dec 2022 | 13504705000000 | 7.32T | 54.26% |
| Mar 2023 | 13957750000000 | 7.60T | 54.47% |
| Mar 2024 | 15108792000000 | 7.83T | 51.86% |
| Dec 2021 | 347.51B | -69.13B | -168.06B |
|---|---|---|---|
| Mar 2022 | 375.58B | -25.63B | -243.8B |
| Mar 2023 | 293.69B | -438.49B | -6.6B |
| Mar 2024 | 272.47B | -77.06B | -36.53B |
Takeda Pharmaceutical Company Limited alternative data
| Sep 2023 | 49,095 |
|---|---|
| Oct 2023 | 49,095 |
| Nov 2023 | 49,095 |
| Dec 2023 | 49,095 |
| Jan 2024 | 49,095 |
| Feb 2024 | 49,095 |
| Mar 2024 | 49,095 |
| Apr 2024 | 49,095 |
| May 2024 | 49,095 |
| Jun 2024 | 49,095 |
| Jul 2024 | 49,281 |
Takeda Pharmaceutical Company Limited other data
3.22%
-1.08%
of TAK is owned by hedge funds
217
-52
50.77M
-17.09M
shares is hold by hedge funds
| Patent |
|---|
Grant Utility: Heterocyclic compounds Filling date: 4 Oct 2018 Issue date: 20 Sep 2022 |
Grant Filling date: 6 Mar 2020 Issue date: 13 Sep 2022 |
Grant Utility: Anti-CD38 antibodies Filling date: 17 Oct 2019 Issue date: 6 Sep 2022 |
Grant Filling date: 17 Mar 2014 Issue date: 6 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 7 Mar 2022 Issue date: 1 Sep 2022 |
Application Filling date: 28 Jul 2020 Issue date: 1 Sep 2022 |
Application Filling date: 7 Jul 2020 Issue date: 1 Sep 2022 |
Grant Filling date: 26 Mar 2018 Issue date: 30 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 9 May 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Feb 2024 | Q3 2023 Earnings Call Transcript |
| Q2 2023 26 Oct 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 27 Jul 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Christophe Weber (1966) Pres, Chief Executive Officer & Representative Director | $12,980,000 |
Dr. Andrew S. Plump (1965) Pres of R&D and Representative Director | $6,680,000 |
Mr. Constantine Saroukos (1971) Chief Financial Officer & Representative Director | $4,690,000 |
Mr. Yasuhiko Yamanaka (1956) Advisor | $329,990 |
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector
Amgen: Imdelltra Data And Q1 Results Impress
Why Investors Should Watch Teva Despite Regional Risks
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating
Top 4 Immunology Stocks Poised For Growth In 2025
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
-
What's the price of Takeda Pharmaceutical Company Limited stock today?
One share of Takeda Pharmaceutical Company Limited stock can currently be purchased for approximately $15.2.
-
When is Takeda Pharmaceutical Company Limited's next earnings date?
Unfortunately, Takeda Pharmaceutical Company Limited's (TAK) next earnings date is currently unknown.
-
Does Takeda Pharmaceutical Company Limited pay dividends?
Yes, Takeda Pharmaceutical Company Limited pays dividends and its trailing 12-month yield is 3.84% with 102% payout ratio.It means that the company is paying a dividend greater than earnings. The last Takeda Pharmaceutical Company Limited stock dividend of $0.4 was paid on 27 Sep 2025.
-
How much money does Takeda Pharmaceutical Company Limited make?
Takeda Pharmaceutical Company Limited has a market capitalization of 41.45B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.47% to 4.26T US dollars. Takeda Pharmaceutical Company Limited earned 144.07B US dollars in net income (profit) last year or $0.52 on an earnings per share basis.
-
What is Takeda Pharmaceutical Company Limited's stock symbol?
Takeda Pharmaceutical Company Limited is traded on the NYSE under the ticker symbol "TAK".
-
What is Takeda Pharmaceutical Company Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Takeda Pharmaceutical Company Limited?
Shares of Takeda Pharmaceutical Company Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Takeda Pharmaceutical Company Limited's key executives?
Takeda Pharmaceutical Company Limited's management team includes the following people:
- Mr. Christophe Weber Pres, Chief Executive Officer & Representative Director(age: 59, pay: $12,980,000)
- Dr. Andrew S. Plump Pres of R&D and Representative Director(age: 60, pay: $6,680,000)
- Mr. Constantine Saroukos Chief Financial Officer & Representative Director(age: 54, pay: $4,690,000)
- Mr. Yasuhiko Yamanaka Advisor(age: 69, pay: $329,990)
-
How many employees does Takeda Pharmaceutical Company Limited have?
As Jul 2024, Takeda Pharmaceutical Company Limited employs 49,281 workers, which is 0% more then previous month and 0% more then previous quarter.
-
When Takeda Pharmaceutical Company Limited went public?
Takeda Pharmaceutical Company Limited is publicly traded company for more then 15 years since IPO on 5 Jan 2010.
-
What is Takeda Pharmaceutical Company Limited's official website?
The official website for Takeda Pharmaceutical Company Limited is takeda.com.
-
How can i contact Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited can be reached via phone at +81 3 3278 2111.
Takeda Pharmaceutical Company Limited company profile:
Takeda Pharmaceutical Company Limited
takeda.comExchange:
NYSE
Full time employees:
49,281
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
1-1, Nihonbashi-Honcho 2-chome
Tokyo, 103-8668
Tokyo, 103-8668
CIK: 0001395064
ISIN: US8740602052
CUSIP: 874060205
